Landmark Science Launches Danish Subsidiary to Accelerate Real-World Evidence and HEOR Across Europe
New Danish branch expands Landmark's European footprint and enables faster, compliant RWE and HEOR for biopharma and medtech AARHUS, Denmark — April 27, 2026 — Landmark Science, Inc. today announced the opening of its new Danish subsidiary, Landmark Science ApS, underscoring the company’s commitment to delivering high quality real world evidence (RWE) and health economics and outcomes research (HEOR) across Europe. Establishing a dedicated presence in Denmark positions Landmark Science to partner closely with European life sciences organizations, health systems, and data partners to generate robust, decision grade evidence for regulatory, market access, and clinical adoption needs. “Across Europe, payers, regulators, and clinicians are increasingly relying on high quality real-world data to evaluate how therapies perform in diverse patient populations,” said Shivani Aggarwal, CEO of Landmark Science. “With Landmark Science ApS, we are deepening our roots in Europe to help meet our clie
